Literature DB >> 32209814

Direct-acting antivirals and viral RNA targeting for hepatitis B cure.

Janine French1,2,3, Stephen Locarnini4, Fabien Zoulim1,2.   

Abstract

PURPOSE OF REVIEW: The current aim in the HBV landscape is to develop therapeutic strategies to achieve a functional cure of infection, characterized by a sustained loss of HBsAg off-treatment. Current treatment options, that is, nucleos(t)ide analogues and IFN are effective at viral suppression but very poor at achieving HBsAg loss. This article is designed to summarize the HBV life cycle in order to review the current treatment strategies and compounds targeting different points of the virus life cycle, which are either in preclinical or clinical phases. RECENT
FINDINGS: Recently our developed understanding of the HBV life cycle has enabled the development of multiple novel treatment options, all aiming for functional cure.
SUMMARY: It is likely that combinations of novel treatments will be needed to achieve a functional cure, including those that target the virus itself as well as those that target the immune system.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32209814     DOI: 10.1097/COH.0000000000000622

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  3 in total

1.  Effect of Hepatocyte Targeting Nanopreparation Syringopicroside on Duck Hepatitis B Virus and Evaluation of Its Safety.

Authors:  X W Zhang; M C Li; J J Dou
Journal:  Bull Exp Biol Med       Date:  2022-03-30       Impact factor: 0.804

Review 2.  HBV-Integration Studies in the Clinic: Role in the Natural History of Infection.

Authors:  Teresa Pollicino; Giuseppe Caminiti
Journal:  Viruses       Date:  2021-02-26       Impact factor: 5.048

3.  Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection.

Authors:  Sarah Kadelka; Harel Dahari; Stanca M Ciupe
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.